About the Company
baudax bio, inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. its lead product candidate is intravenous form of meloxicam, a non-opioid that has completed phase iii clinical trials for the management of moderate to severe pain; and is in the phase iiib clinical trials in colorectal surgery and orthopedic surgery patients to assess opioid consumption, pain intensity, and length of hospital stay with associated pharmacoeconomic parameters. the company's early-stage product candidates includes rp1000, an intermediate-acting neuromuscular blocking agent (nmba) that is in phase i clinical trial; and rp2000, an ultrashort-acting nmba, which is in pre-clinical trial; and a reversal agent, as well as dex-in, a proprietary intranasal formulation of dexmedetomidine. the company was incorporated in 2019 and is based in malvern, pennsylvania.
Exchange
OTC MARKETS
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $BXRX News
Which Is a Better Investment, Janux Therapeutics Inc or BIO-TECHNE Corp Stock?
Learn more about whether Janux Therapeutics Inc or BIO-TECHNE Corp is a better investment based on AAII's A+ Investor grades, ...
Mustang Bio stock tumbles 27% amid news of mass layoffs
Mustang Bio (MBIO) stock tumbled 27% Monday in the wake of news that the company plans to cut around 81% of its workforce to ...
Bio-Rad (BIO) Hurt by Softness in BioPharma and Competition
Bio-Rad BIO has been facing the impact of funding issues in the biopharmaceutical or BioPharma space, macroeconomic headwinds ...
Should You Invest in Coherus Biosciences Inc (CHRS) Now?
In conclusion, Coherus Biosciences Inc (CHRS) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important ...
BioXcel Therapeutics Inc (BTAI) Stock: A SWOT Analysis
Steinhart Richard I, the Chief Financial Officer of BioXcel Therapeutics Inc, sale 1,069 shares at $2.63 during a trade that took place back on Apr 04 ’24, which means that Steinhart Richard I is ...
Which Is a Better Investment, Celldex Therapeutics, Inc. or BIO-TECHNE Corp Stock?
Learn more about whether Celldex Therapeutics, Inc. or BIO-TECHNE Corp is a better investment based on AAII's A+ Investor ...
Loading the latest forecasts...